GLP-1 Prescriptions for Prediabetes: Coverage, Eligibility, and the New Medicare Path
Prediabetes affects roughly 98 million American adults — and it's one of the qualifying conditions for GLP-1 prescriptions under both FDA labeling and the new Medicare GLP-1 Bridge program launching July 2026. If your A1C is between 5.7% and 6.4%, you may have more medication options than you realize.
Why Prediabetes Matters for GLP-1 Access
Prediabetes is a recognized weight-related comorbidity under both FDA labeling and insurance criteria. This means:
- FDA eligibility: If your BMI is 27–29.9 and you have prediabetes, you meet the Tier 2 criteria for Wegovy and Zepbound prescriptions
- Insurance: Prediabetes strengthens your prior authorization case significantly. Plans are more likely to approve GLP-1s when there's a metabolic diagnosis beyond obesity alone
- Medicare Bridge: Prediabetes is a Phase 1 qualifying comorbidity. With BMI ≥ 27 and documented prediabetes, you qualify for $50/mo copays starting July 2026
The Diabetes vs. Weight Loss Prescription Strategy
Insurance coverage for GLP-1 medications differs dramatically based on the diagnosis code your doctor uses:
- Prescribed for type 2 diabetes: Covered by approximately 85% of commercial plans (Ozempic, Mounjaro)
- Prescribed for weight management: Covered by approximately 45% of commercial plans (Wegovy, Zepbound)
If you have prediabetes, your doctor has clinical options. While Ozempic and Mounjaro are indicated for type 2 diabetes (not prediabetes), some providers consider GLP-1 therapy for metabolic management that includes prediabetes risk reduction. This is a clinical decision between you and your physician.
Rybelsus (oral semaglutide 7mg and 14mg) has an expanded FDA indication that includes reducing cardiovascular risk in adults with T2D. If your prediabetes has progressed to T2D, this opens additional coverage pathways.
Documenting Prediabetes for Your Prescription
To use prediabetes as a qualifying comorbidity, you'll need:
- A1C test result between 5.7% and 6.4% (or fasting glucose 100–125 mg/dL)
- Documentation date within the last 6–12 months
- Your doctor's assessment noting prediabetes as a reason for GLP-1 therapy
These results should be included in any prior authorization submission or insurance appeal.
Getting Started
If you have prediabetes and a BMI ≥ 27, you have strong eligibility for GLP-1 therapy. These providers can evaluate you and discuss your options: